Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer

Author:

Wang Jie1,Lu Shun2,Yu Xinmin3,Hu Yanping4,Sun Yuping5,Wang Zhijie1,Zhao Jun6,Yu Yan7,Hu Chunhong8,Yang Kunyu9,Feng Guosheng10,Ying Kejing11,Zhuang Wu12,Zhou Jianying13,Wu Jingxun14,Leaw Shiang Jiin15,Zhang Jing15,Lin Xiao15,Liang Liang15,Yang Nong16

Affiliation:

1. State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

2. Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

3. Zhejiang Cancer Hospital, Hangzhou, China

4. Hubei Cancer Hospital, Wuhan, China

5. Jinan Central Hospital, Shandong, China

6. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Beijing, China

7. Harbin Medical University Cancer Hospital, Harbin, China

8. The Second Hospital of Central South University, Changsha, China

9. Union Hospital Tongji Medical College Huazhong University of Science and Technology, Hubei, China

10. The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China

11. Sir Run Shaw Hospital, Zhejiang University, School of Medicine, Zhejiang, China

12. Fujian Tumor Hospital, Fuzhou, China

13. The First Affiliated Hospital, Zhejiang University, Zhejiang, China

14. The First Affiliated Hospital of Xiamen University, Fujian, China

15. BeiGene (Beijing) Co, Ltd, Beijing, China

16. Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3